The effect of 12 weeks carnosine supplementation on renal functional integrity and oxidative stress in pediatric patients with diabetic nephropathy: a randomized placebo‐controlled trial
What this study found
Twelve weeks of L-carnosine produced favorable changes in renal and oxidative stress markers and improved glycemic control. In the carnosine group, HbA1c fell from 8.2 AE 2.1 to 7.4 AE 1.3, UACR decreased from 91.7 (56-136.5) to 38.5 (15-50.5) mg/g creatinine, and alpha 1-microglobulin declined from 16.5 AE 6.8 to 9.3 AE 6.6 mg/L. Oxidative stress improved, with TAC rising from 2.6 AE 0.7 to 3.4 AE 1.0 mmol/L and MDA falling from 25.5 AE 8.1 to 18.2 AE 7.7 nmol/mL. Serum carnosine increased from 106.2 AE 11.7 to 910 AE 24.1 ng/mL, and no adverse reactions were reported. The authors concluded…
- Study & population
- Randomized, placebo-controlled trial in pediatric patients with type 1 diabetes and diabetic nephropathy with persistent microalbuminuria despite ACE-inhibitor therapy.
- Intervention
- Oral L-carnosine was given at 1 g/day (500 mg twice daily) for 12 weeks, added to standard therapy and compared with placebo.
- Key limitation
- The study was short, with only 12 weeks of follow-up, so durability of benefit is unknown.
View source
Open PDFOriginal abstract
Oxidative stress is a significant contributor to the pathogenesis of diabetic nephropathy. Carnosine is a natural radical oxygen species scavenger. We investigated the effect of carnosine as an adjuvant therapy on urinary albumin excretion (UAE), the tubular damage marker alpha 1‐microglobulin (A1M), and oxidative stress in pediatric patients with type 1 diabetes and nephropathy.